Akari Therapeutics (NASDAQ: AKTX) reported a widened net loss for the second quarter of 2026, reflecting increased investment in its lead antibody drug conjugate (ADC) candidate, AKTX-101. The Tampa-based oncology biotechnology company posted a net loss of $4.8 million for the three months ended June 30, 2026, compared to a net loss of $1.9 million in the second quarter of 2025.

The expansion in the deficit was primarily driven by higher research and development (R&D) expenses, which rose to $2.1 million from $0.7 million a year earlier. This increase supports IND-enabling activities and manufacturing work required to initiate Phase 1 clinical trials for AKTX-101, which are planned for mid-2027. General and administrative (G&A) expenses remained stable at $2.5 million, unchanged from the prior-year period.

Financial Position and Capital Raise

Despite the operating losses, Akari strengthened its balance sheet during the quarter through strategic financing. The company secured approximately $8.6 million in gross proceeds, comprising $5.5 million from a private placement and $3.1 million from warrant exercises. After costs, the company received approximately $8.0 million in net proceeds.

As of June 30, 2026, cash totaled $7.7 million, an increase from $5.2 million as of December 31, 2025. The infusion of capital, led by long-term strategic investors, is intended to support the continued advancement of AKTX-101 towards the clinic and expand the company’s ADC payload platform.

*Cash as of December 31, 2025.

What the Numbers Show

The financial data highlights a clear shift in capital allocation towards clinical readiness. R&D expenses tripled year-over-year, accounting for roughly 44% of the total quarterly burn rate ($4.8 million net loss + non-cash items implied by expense structure, though strictly based on disclosed expenses: $2.1M R&D + $2.5M G&A = $4.6M total expenses vs $4.8M net loss). The significant increase in R&D spending directly correlates with the company’s timeline to initiate Phase 1 trials in mid-2027, indicating that near-term losses will likely remain elevated as manufacturing and regulatory preparations accelerate. Meanwhile, the successful raise of $8.6 million provides a critical buffer, extending the runway for these preclinical-to-clinical transition activities.

Pipeline and Strategic Updates

Beyond financial results, Akari highlighted progress in its scientific platform:

• AKTX-101 Advancement: The company continues IND-enabling activities for its lead candidate, which targets the Trop2 receptor using a novel PH1 spliceosome-modulating payload. Preclinical data presented at ASCO 2026 demonstrated synergistic anti-tumor activity when PH1 was combined with a KRAS inhibitor in pancreatic cancer models.
• Whitehawk Collaboration: Akari entered a research collaboration with Whitehawk Therapeutics to explore dual-payload ADCs. This partnership combines Akari’s PH1 payload with Whitehawk’s topoisomerase I payload platform to investigate synergistic anti-tumor effects.
• Intellectual Property: The company expanded its IP portfolio with newly issued international patents for its PH1 technology, strengthening long-term protection for its platform.

Akari Therapeutics announced a strategic research collaboration with Whitehawk Therapeutics to expand the potential application of its PH1 platform into dual-payload antibody-drug conjugates (ADCs). The agreement focuses on evaluating Akari's proprietary PH1 spliceosome modulating payload in combination with Whitehawk's topoisomerase I payload technology.

The collaboration is designed to investigate the potential of combining these complementary ADC payload technologies. The companies aim to synergize and enhance anti-tumor activity through this dual-payload approach.

Strategic Implications

This partnership expands Akari's strategic position in novel ADC payloads. The move demonstrates continued strong interest in ADC payload innovation across the biotech and pharmaceutical sectors.

The collaboration highlights the unique potential of the PH1 payload by testing it alongside another established mechanism of action. By combining spliceosome modulation with topoisomerase I inhibition, the research seeks to identify synergistic effects that may improve therapeutic outcomes compared to single-payload approaches.